# Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

> **NCT07376499** · PHASE2 · NOT_YET_RECRUITING · sponsor: **China Medical University, China** · enrollment: 31 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Liposome Irinotecan
- **DRUG:** Platinum
- **DRUG:** Anlotinib
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07376499
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-25
- **Primary completion:** 2026-03-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07376499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07376499, "Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07376499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*